Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Primary biliary cholangitis (previously known as Primary biliary cirrhosis) Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) a nurse practitioner who is continuing treatment with this medicine (of any strength) that was initiated by a medical practitioner as a PBS benefit.
“However, ursodeoxycholic acid alters bile acid composition, resulting in increases in the concentration of ursodeoxycholic acid and decreases in the concentrations of the more hydrophobic and potentially toxic bile acids, cholic and chenodeoxycholic acids.”
“The biological half-life, obtained by radioactive labelling, of orally administered ursodeoxycholic acid is 3.5 - 5.8 days due to the effective enterohepatic circulation of ursodeoxycholic acid in the body.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“On the basis of this, together with a single case report of an interaction with the substance dapsone (reduction of the therapeutic effect) and in vitro findings, it may be assumed that ursodeoxycholic acid induces the medicinal product-metabolising enzyme cytochrome P450 3A4.”